CLAIMS:

1. The use of a compound of Formula (I):



Formula (I)

wherein:

X and **Y** are independently selected from: oxygen, sulphur and $(-CR^aR^b-)_n$; wherein:

n is an integer of from 1 to 4 and

R^a and R^b are each independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, hydroxy, C_{1-6}alkanoyloxy, C_{3-12}cycloalkyl and optionally substituted phenyl or R^a and R^btogether form a C_{5-12}spirocycloalkyl or a carbonyl;

with the proviso that at least one of **X** and **Y** is $(-CR^aR^b-)_n$ and with the further proviso that when **X** and **Y** are both $(-CR^aR^b-)_n$ and R^a and R^b are hydrogen and **n** is 1, then R^1 and R^3 are both aryl;

R^2 is hydrogen, a C_{1-8}alkyl or benzyl;

R^1 and R^3 are independently selected from

(a) phenyl or phenoxy wherein the phenyl or phenoxy group is optionally substituted with 1 to 5 substituents independently selected from

phenyl, C_{1-6}alkyl, C_{1-6}alkoxy, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, carboxy, C_{1-4}alkoxycarbony and $-(CH_2)_pNR_4R_5$ wherein **p** is 0 or 1, and R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl;

(b) naphth-1-yl or naphth-2-yl wherein the naphthyl group is optionall substituted with from 1 to 3 substituents independently selected from

phenyl, C_{1-6}alkyl, C_{1-6}alkoxy, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, carboxy, C_{1-4}alkoxycarbony and $-(CH_2)_pNR_4R_5$ wherein **p**, R^4 and R^5 are as defined above;

(c) arylC_{1-6}alkyl;

(d) C_{1-20}alkyl or C_{1-20}alkenyl; and

(e) adamantyl or a C_{3-12}cycloalkyl;

or a pharmaceutically acceptable salt, pro-drug or solvate thereof in the manufacture of a medicament for the treatment of diabetes and/or obesity.

2. The use according to claim 1 wherein $\mathbf{R^1}$ is phenyl.

3. The use according to claim 2 wherein $\mathbf{R^1}$ is phenyl disubstituted in the 2,6-positions.

4. The use according to any one of claims 1, 2 or 3 wherein $\mathbf{R^3}$ is phenyl.

5. The use according to claim 4 wherein $\mathbf{R^3}$ is phenyl disubstituted in the 2,6-positions.

6. The use according to claim 1 wherein $\mathbf{R^1}$ is phenyl disubstituted in the 2,6-positions and $\mathbf{R^3}$ is phenyl trisubstituted in the 2,4,6-positions.

7. The use according to claim 1 wherein $\mathbf{R^1}$ is 2,6-bis(1-methylethyl)phenyl and $\mathbf{R^3}$ is 2,6-bis(1-methylethyl)phenyl or 2,4,6-tris(1-methylethyl)phenyl.

8. The use according to claim 1 wherein:
one of $\mathbf{R^1}$ and $\mathbf{R^3}$ is the group



wherein

t is 0 to 4;

w is 0 to 4 with the proviso that the sum of **t** and **w** is not greater than 5;

$\mathbf{R^6}$ and $\mathbf{R^7}$ are independently selected from hydrogen or C_{1-6}alkyl, or when $\mathbf{R^6}$ is hydrogen, $\mathbf{R^7}$ can be selected from the groups defined for $\mathbf{R^8}$; and $\mathbf{R^8}$ is phenyl optionally substituted with from 1 to 3 substituents selected C_{1-6}alkyl C_{1-6}alkoxy , phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, carboxy, C_{1-4}alkoxycarbonyl, or -(CH_2)**p**N$\mathbf{R^4R^5}$ wherein **p**, $\mathbf{R^4}$ and $\mathbf{R^5}$ are as defined above.

9. The use according to claim 1 wherein

X is oxygen;

Y is $(CR^aR^b)_n$ wherein

n is an integer of from 1 to 4 and

R^a and R^b are each independently hydrogen, C_{1-6}alkyl, optionally substituted phenyl, halo, hydroxy, C_{1-6}alkoxy, C_{1-6}alkanoyloxy, cycloalkyl, or R^a and R^b taken together form a carbonyl or C_{3-10}spirocycloalkyl;

R^1 is selected from optionally substituted phenyl, C_{1-10}alkyl or C_{3-10}cycloalkyl;

R^2 is hydrogen;

R^3 is selected from optionally substituted phenyl, C_{1-10}alkyl, C_{3-8}cycloalkyl and optionally substituted phenoxy.

10. The use according to claim 1 wherein

X is oxygen;

Y is $(CR^aR^b)_n$ wherein n is an integer of from 1 to 2;

R^1 is optionally substituted phenyl;

R^2 is hydrogen;

R^3 is selected from optionally substituted phenyl, optionally substituted phenoxy, C_{1-10}alkyl, and C_{3-10}cycloalkyl;

R^a and R^b are independently selected from hydrogen, C_{1-6}alkyl, optionally substituted phenyl, halogen, hydroxy, C_{1-6}alkoxy, C_{1-6}alkanoyloxy, cycloalkyl, or R^a and R^b taken together form a carbonyl or a spirocycloalkyl.

11. The use according to claim 1 wherein

X is oxygen;

Y is (-CR^aR^b-)n wherein n is an integer of from 1 to 4 and R' and R" are each independently hydrogen, alkyl, alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, phenyl optionally substituted or R' and R" together form a spirocycloalkyl or a carbonyl;

R^1 and R^3 are independently selected from

(a) phenyl or phenoxy wherein the phenyl or phenoxy group is optionally substituted with 1 to 5 substituents independently selected from

phenyl, C_{1-6}alkyl, C_{1-6}alkoxy, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, carboxy, C_{1-4}alkoxycarbony and $-(CH_2)_pNR_4R_5$ wherein p is 0 or 1, and R^4 and R^5 are independently selected from hydrogen or C_{1-4}alkyl;

(b) naphth-1-yl or naphth-2-yl wherein the naphthyl group is optionally substituted with from 1 to 3 substituents independently selected from

phenyl, C_{1-6}alkyl, C_{1-6}alkoxy, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, carboxy, C_{1-4}alkoxycarbony and-$(CH_2)_pNR_4R_5$ wherein **p**, R^4 and R^5 are as defined above;

(c) arylC_{1-6}alkyl;

(d) C_{1-20}alkyl or C_{1-20}alkenyl; and

(e) adamantyl or a C_{3-12}cycloalkyl

R^2 is hydrogen, a C_{1-8}alkyl or benzyl;

12. The use according to claim 1 wherein the compound is selected from:

Sulfamic acid (phenylacetyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl-2,4,6-tris(1-methylethyl)phenyl ester,

Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,4,6-tris(1-methylethyl)phenyl ester,

Sulfamic acid[adamantaneacetyl]-2,6-bis[1-methylethyl)phenyl ester,

Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt,

Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt,

Sulfamic acid (decanoyl)-2,6-bis-(1-methylethyl)phenyl ester,

Sulfamic acid (dodecanoyl)-2,6-bis-(1-methylethyl)phenyl ester,

2. 6-Bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]methyl]sulfonyl] benzeneacetamide,

2,6-Bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]methyl]sulfonyl] benzeneacetamide-sodium salt.

2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris(1-methylethyl)phenyl]methyl]sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris(1-methylethyl)phenyl]methyl]sulfonyl]carbamate-sodium salt,

Sulfamic acid (1-oxo-3,3-diphenylpropyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [2,6-dichlorophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [2,6-dichlorophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid trans-[(2-phenylcyclopropyl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [2,5-dimethoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [2,4,6-trimethoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [2,4,6-trimethylphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [2-thiophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [3-thiophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [2-methoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (oxophenylacetyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [2-trifluoromethylphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (1-oxo-2-phenylpropyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (cyclopentylphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (cyclohexylacetyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (diphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (triphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [(1l-phenylcyclopentyl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (1-oxo-2-phenylbutyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (cyclohexylphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (1-oxo-2,2-diphenylpropyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [(9H-fluoren-9-yl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid (1-oxo-3-phenylpropyl)-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)phenyl-2-propenyl]-2,6-bis(1-methylethy l)phenyl ester,

Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)phenyl]propyl]-2,6-bis(1-methylethyl)ph enyl ester,

Sulfamic acid [(acetyloxy)[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [hydroxy[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phe nyl ester,

Sulfamic acid [fluoro[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phen yl ester,

Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-2,6-bis(1-methylethyl)phenyl ester sodium salt,

Sulfamic acid [[2,4,6-tris(1-methylethyl)phenoxy]acetyl]-2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [[2,6-bis(1-methylethyl)phenoxy]acetyl]-2,6-bis(1-methylethyl)phenyl ester, and

Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(phenyl)phenyl ester.

or pharmaceutically acceptable salt, pro-drug or solvate.

13. The use according to claim 1 wherein the compound is:
sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]acetyl-2,6-bis(1-methylethyl)phenyl ester.

or pharmaceutically acceptable salt, pro-drug or solvate.

14. The use according to any one of the preceding claims wherein the use is the manufacture of a medicament for the treatment of type II diabetes.

15. The use according to any one of the preceding claims wherein the use is the manufacture of a medicament for the treatment of obesity.

16. The use according to any one of the preceding claims wherein the use is the manufacture of a medicament for the treatment of insulin resistance.

17. The use according to any one of the preceding claims wherein the use is the manufacture of a medicament for the treatment of impaired glucose tolerance.